COVID-19 Co-infection in a patient with Crimean Congo Hemorrhagic Fever: A Case Report


Creative Commons License

Büyüktuna S. A., Hasbek M., Oksuz C., Baysal C., Öz M., Elaldı N., ...Daha Fazla

MIKROBIYOLOJI BULTENI, cilt.55, sa.3, ss.445-451, 2021 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 55 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.5578/mb.20219813
  • Dergi Adı: MIKROBIYOLOJI BULTENI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, EMBASE, MEDLINE, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.445-451
  • Anahtar Kelimeler: Co-infection, COVID-19, CCHF, EFFICACY, PARAMETERS, RIBAVIRIN
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Crimean-Congo Hemorrhagic Fever (CCHF) is an acute viral zoonotic disease. Coronavirus disease-2019 (COVID-19) is a newly emerging viral disease and it is caused by "severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)". In this article, a case diagnosed with CCHF and COVID-19 coinfection confirmed by the polymerase chain reaction (PCR) method and its management was presented. A thirty-five years old female patient admitted to the hospital with the complaint of fever for one day and common body pain. It was learned that three days before the onset of her complaints, she removed a tick adhering to the anterior abdominal wall with no precaution. Her body temperature was 38 degrees C degrees and her respiratory rate was 22 per minute. The leucocyte count was 3660/mm(3) and the platelet count was 138.000/mm(3). It was determined that prothrombin time was 15.4 seconds, international normalized ratio (INR) was 1.35 seconds, and D-dimer level was 1310 ng/ml. The patient was hospitalized with prediagnosis of CCHF. Supportive treatment was started. On the second day at the clinical follow-up of the patient, complaints of sore throat and cough without sputum started. A combined nasopharyngeal and throat swab sample was taken from the patient because of the suspicion of COVID-19. COVID-19 PCR test result was reported as positive. Favipiravir treatment was started. The CCHF-PCR test, which was studied from the serum sample sent to the Microbiology Reference Laboratories was reported as positive. From the third day of favipiravir treatment; the patient did not have a fever and her complaints regressed. On the ninth day of her hospitalization, she was discharged. In this case; it is important to show that both diseases, especially in regions where CCHF disease is endemic, can be confused due to the similarity of the clinical picture with COVID-19 and to know that they can coexist.